[Efficacy and safety of Mizolastine in the treatment of perennial allergic rhinitis].
OBJECTIVE
To investigate the efficacy and safety of Mizolastine in the treatment of perennial allergic rhinitis.


METHODS
Multicentric random Double-blind parallel-controlled study was adopted, and compared with placebo and Cetirizine. Patients (n = 177) were grouped, seventy-two in Mizolastine group, sixty-nine in Cetirizine and thirty-six in placebo group.


RESULTS
In the seventh curative day symptomatic and sign marks in Mizolastine group and Cetirizine group were lower, but the mark in Mizolastine group reduced more than in Cetirizine group and placebo group. Mizolastine group is better than Cetirizine group in improvement of nasal obstruction and itching with Visual analogue scale. In the twenty first curative day reduction of symptomatic and sign marks in Mizolastine group was lower than Cetirizine group, but no statistic difference. There were 27 adverse events, no serious adverse events in 177 patients during experimental period. Most adverse events were headache and dryness in mouth and eyes. There were 10 cases adverse events in Mizolastine group, one case was related with experiment and four cases might be related with experiment. There were 14 cases adverse events in Cetirizine group, one case was related with experiment and four cases might be related with experiment. There were three cases adverse events in placebo group.


CONCLUSIONS
Generally speaking the efficacy of Mizolastine in treatment of perennial allergic rhinitis is better than Cetirizine, Bad events are less. It is safe.
Zhou
Shuimiao
S
Department of Otolaryngology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. zhousm208@hotmail.com
Ding
Jingcheng
J
Zheng
Chunquan
C
Wang
Hongtian
H
Huang
Zhigang
Z
D000293:Adolescent; D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D017332:Cetirizine / Q000627:therapeutic use; D002648:Child; D004311:Double-Blind Method; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D001562:Benzimidazoles; D039563:Histamine H1 Antagonists, Non-Sedating; C076170:mizolastine; D017332:Cetirizine